Slide 1: DISSOLVE I & II Phase 3 Clinical Trials: Topline Data
Exhibit 99.2 SELB DISSOLVE I & II Phase 3 Clinical Trials: Topline Data For release on March 21, 2023
Slide 2: Forward-looking statements
Forward-looking statements Any statements in this presentation about the future expectations, plans and prospects of Selecta Biosciences, Inc. (the “Company”), including without limitation, statements regarding the Company’s cash runway, the unique proprietary technology platform of the Company, and
Slide 3: Both Phase 3 Studies and both tested doses met primary efficacy endpoints
Both Phase 3 Studies and both tested doses met primary efficacy endpoints, achieving a statistically significant response rate with SEL-212 versus placebo § The response rate in the high dose group was 56% in DISSOLVE I (the US Study ) and 47% in DISSOLVE II (the Global Study ) § The response rate i
Slide 4: SEL-212 is a combination of pegadricase plus ImmTOR for treatment of chronic refractory gout
SEL-212 is a combination of pegadricase plus ImmTOR for treatment of chronic refractory gout § Pegadricase is a novel and potent yeast uricase enzyme that converts serum urate (SU) into a highly water-soluble molecule that is readily excreted in the urine § While pegadricase markedly reduces SU, it
Slide 5: Two randomized double-blind, placebo-controlled Phase 3 studies of SEL-212 in refractory gout
Two randomized double-blind, placebo-controlled Phase 3 studies of SEL-212 in patients with gout refractory to conventional therapy Both studies have three arms, randomized 1:1:1 to a single dose in each 2 -d 8 ay treatment period (TP): High dose - 0.15 SEL-212 Low dose - 0.1 SEL-212 Placebo IV infu
Slide 6: Subject flow
Subject flow Global Study US Study DISSOLVE II DISSOLVE I SCREENED SCREENED 413 486 328 initially screen failed 298 initially screen failed RANDOMIZED RANDOMIZED 115 158 5 not dosed (subsequently screen failed) 3 not dosed (subsequently screen failed) RANDOMIZED & DOSED RANDOMIZED & DOSED Intention
Slide 7: Baseline demographic characteristics
Baseline demographic characteristics Balanced for age, BMI, sex, and race across treatment groups in both studies US Study (DISSOLVE I) Global Study (DISSOLVE II) Treatment Group High dose Low dose Placebo Total High dose Low dose Placebo Total (Number-ITT) (38) (37) (37) (112) (49) (51) (53) (153)
Slide 8: Baseline disease characteristics
Baseline disease characteristics • Baseline characteristics were reasonably well balanced across treatment groups in each study • Gout severity was somewhat greater in the Global Study versus the US Study US Study (DISSOLVE I) Global Study (DISSOLVE II) Treatment Group High dose Low dose Placebo Tot
Slide 9: Both studies and tested doses met primary efficacy endpoints
Both studies and tested doses met primary efficacy endpoints • Percent responders in the high dose group was 56% and 47% for US & Global Studies, respectively • Percent responders in the low dose group was 48% and 41% for US & Global Studies, respectively • Results are consistent across multiple mod
Slide 10: Responders in patients ≥50 years old
Responders in patients ≥ 50 years old 1 • Pre-determined endpoint for largest age group population • Percent responders in the high dose group was 65% and 48% for US & Global Studies, respectively US Study (DISSOLVE I) Global Study (DISSOLVE II) High dose Low dose Placebo High dose Low dose Placebo
Slide 11: Key secondary endpoints: Mean and percent reduction in serum urate
Key secondary endpoints: Mean and percent reduction in serum urate • Marked reduction of serum urate in both studies and for both low and high dose groups • Other secondary endpoints are not yet available US St udy (DISSOLVE I) Global St udy (DISSOLVE II) High dose Low dose Placebo High dose Low dos
Slide 12: All adverse events of special interest (AESI)
1 All adverse events of special interest (AESI) • No difference in gout flares between treatment groups and placebo • Stomatitis in treatment groups (3.4-9.2%), all mild to moderate intensity • Low incidence of infusion reactions (3.4%-4.5%) in high and low dose groups, respectively Pooled St udies
Slide 13: Serious adverse events (SAEs)
Serious adverse events (SAEs) Six subjects (3.4%) in the pooled active treatment groups had an SAE related to treatment Pooled St udies at 6-Mont h Primary Endpoint High dose (87) Low dose (88) Placebo (90) Safety Set n (% ) n (% ) n (% ) Subjects w ith at least 1 SAE 6 (6.9) 13 (14.8) 2 (2.2) 1 2 S
Slide 14: Low incidence of infusion reactions (IRs)
1 Low incidence of infusion reactions (IRs) • IRs occurred in 3.4% of high dose group and in 4.5% of low dose group • All IRs occurred within the first three infusions • All occurred during infusion and completely resolved with stopping infusion and symptomatic treatment Pooled St udies US Study Ext
Slide 15: Majority (75%) of those entering the 6-month extension were responders at 12 months
Majority (75%) of those who entered the 6-month extension phase on active treatment were responders at 12 months with no new safety signals 100% of patients who received dose 12 of active drug were responders in TP12 75% Percent of subjects on active treatment entering TP7 (both dose groups) who 0.1
Slide 16: Both Phase 3 Studies and both tested doses met primary efficacy endpoints
Both Phase 3 Studies and both tested doses met primary efficacy endpoints, achieving a statistically significant response rate with SEL-212 versus placebo § The response rate in the high dose group was 56% in DISSOLVE I (the US Study ) and 47% in DISSOLVE II (the Global Study ) § The response rate i
Slide 17: Phase 3 trials are a massive team effort
Phase 3 trials are a massive team effort Thank you to the entire team but most importantly participating patients & their families clinical sites, principal investigators and clinical staff Clinical team & entire company that contributed to the SEL-212 program Our partner in developing SEL-212 Our C